Celcuity CELC 深 滬
等待開盤 09-24 09:30:00 美东时间
79.99
-4.110
-4.89%
華盛通- 最 高85.05
- 今 開84.93
- 成交量 73.94万股
- 最 低 79.40
- 昨 收 84.10
- 總市值 39.14亿
- 52周最高 151.02
- 市盈率 靜 --
- 換手率 1.51%
- 52周最低 45.03
- 委 比 -4.76%
- 總股本 4893.19万
- 歷史最高 151.02
- 量 比 0.89
- 振 幅 6.72%
- 歷史最低 4.03
- 每 手 1
- 風險率 20.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157
JP Morgan analyst Anupam Rama initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rating and announces Price Target of $157.
09-17 20:02
Most shorted stocks on Wall Street
As September begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 44 stocks with short interest above 20% ...
09-02 22:28
Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application ("sNDA") to the U.S. Food and Drug Administration ("FDA") for REVTORPYK™ (g...
08-26 20:31
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Celcuity shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.
Celcuity shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.
08-14 23:12
Celcuity Analysts Slash Their Forecasts After Q2 Loss
Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday. The company posted quarterly losses of $1.07 per share which beat the analyst consensus estimate of losses of $1.17 per share. This represents a 15.05% decline over losses of 93 cents per share from...
08-14 20:29
Needham Maintains Buy on Celcuity, Lowers Price Target to $140
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $157 to $140.
08-14 18:20
财报速睇 | Celcuity 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.79亿美元，同比亏损扩大74.2%
华盛资讯8月14日讯，Celcuity公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.79亿美元，同比亏损扩大74.2%。
08-14 05:37
